These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 31690270)

  • 21. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
    Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
    Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma.
    Wright TM; Brannon AR; Gordan JD; Mikels AJ; Mitchell C; Chen S; Espinosa I; van de Rijn M; Pruthi R; Wallen E; Edwards L; Nusse R; Rathmell WK
    Oncogene; 2009 Jul; 28(27):2513-23. PubMed ID: 19448672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long Non-Coding RNA LUCAT1 Promotes Proliferation and Invasion in Clear Cell Renal Cell Carcinoma Through AKT/GSK-3β Signaling Pathway.
    Zheng Z; Zhao F; Zhu D; Han J; Chen H; Cai Y; Chen Z; Xie W
    Cell Physiol Biochem; 2018; 48(3):891-904. PubMed ID: 30032137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy.
    Sinha S; Dwivedi N; Tao S; Jamadar A; Kakade VR; Neil MO; Weiss RH; Enders J; Calvet JP; Thomas SM; Rao R
    Oncogene; 2020 Feb; 39(6):1231-1245. PubMed ID: 31616061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma.
    Li T; Cheng Y; Wang P; Wang W; Hu F; Mo X; Lv H; Xu T; Han W
    J Exp Clin Cancer Res; 2015 Oct; 34():122. PubMed ID: 26474560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma.
    Yu H; Liu R; Ma B; Li X; Yen HY; Zhou Y; Krasnoperov V; Xia Z; Zhang X; Bove AM; Buscarini M; Parekh D; Gill IS; Liao Q; Tretiakova M; Quinn D; Zhao J; Gill PS
    Br J Cancer; 2015 Aug; 113(4):616-25. PubMed ID: 26180925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.
    Kruck S; Merseburger AS; Hennenlotter J; Scharpf M; Eyrich C; Amend B; Sievert KD; Stenzl A; Bedke J
    BJU Int; 2012 May; 109(10):1565-70. PubMed ID: 21981759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of CX3CR1 associates with cellular migration, metastasis, and prognosis in human clear cell renal cell carcinoma.
    Yao X; Qi L; Chen X; Du J; Zhang Z; Liu S
    Urol Oncol; 2014 Feb; 32(2):162-70. PubMed ID: 23570708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting renal cell carcinoma with a HIF-2 antagonist.
    Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
    Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
    Sakai I; Miyake H; Fujisawa M
    BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors.
    Simon AG; Esser LK; Ellinger J; Branchi V; Tolkach Y; Müller S; Ritter M; Kristiansen G; Muders MH; Mayr T; Toma MI
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2255-2265. PubMed ID: 32533404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma.
    Morikawa T; Sugiyama A; Kume H; Ota S; Kashima T; Tomita K; Kitamura T; Kodama T; Fukayama M; Aburatani H
    Clin Cancer Res; 2007 Oct; 13(19):5703-9. PubMed ID: 17908959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPR3 and activating p38-MAPK signaling.
    Li JK; Chen C; Liu JY; Shi JZ; Liu SP; Liu B; Wu DS; Fang ZY; Bao Y; Jiang MM; Yuan JH; Qu L; Wang LH
    Mol Cancer; 2017 Jun; 16(1):111. PubMed ID: 28659173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas.
    Komohara Y; Morita T; Annan DA; Horlad H; Ohnishi K; Yamada S; Nakayama T; Kitada S; Suzu S; Kinoshita I; Dosaka-Akita H; Akashi K; Takeya M; Jinushi M
    Cancer Immunol Res; 2015 Sep; 3(9):999-1007. PubMed ID: 25783986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
    Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
    J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High RSK4 expression constitutes a predictor of poor prognosis for patients with clear cell renal carcinoma.
    Ma J; Wang K; Chai J; Xu T; Wei J; Liu Y; Wang Y; Xu J; Li M; Fan L
    Pathol Res Pract; 2021 Nov; 227():153642. PubMed ID: 34649054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer.
    Gockel I; Moehler M; Frerichs K; Drescher D; Trinh TT; Duenschede F; Borschitz T; Schimanski K; Biesterfeld S; Herzer K; Galle PR; Lang H; Junginger T; Schimanski CC
    Oncol Rep; 2008 Oct; 20(4):845-50. PubMed ID: 18813825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical expression of CD44, matrix metalloproteinase2 and matrix metalloproteinase9 in renal cell carcinomas.
    Lee YM; Kim JM; Lee HJ; Seong IO; Kim KH
    Urol Oncol; 2019 Oct; 37(10):742-748. PubMed ID: 31053527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma.
    García-Alonso S; Romero-Pérez I; Gandullo-Sánchez L; Chinchilla L; Ocaña A; Montero JC; Pandiella A
    J Exp Clin Cancer Res; 2021 Aug; 40(1):256. PubMed ID: 34399807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor.
    Schiefer AI; Mesteri I; Berghoff AS; Haitel A; Schmidinger M; Preusser M; Birner P
    Histopathology; 2015 Dec; 67(6):799-805. PubMed ID: 25847631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.